Resul'taty primeneniia éndovaskuliarnykh vmeshatel'stv (émbolizatsii i khimioèmbolizatsii) v lechenii operabel'nogo i rasprostranennogo raka pochki. / Granov, A. M.; Gorelov, A. I.; Gershanovich, M. L.; Karelin, M. I.; Vorob'ev, A. V.; Filov, V. A.; Stukov, A. N.
In: Voprosy Onkologii, Vol. 44, No. 6, 1998, p. 711-714.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Resul'taty primeneniia éndovaskuliarnykh vmeshatel'stv (émbolizatsii i khimioèmbolizatsii) v lechenii operabel'nogo i rasprostranennogo raka pochki.
AU - Granov, A. M.
AU - Gorelov, A. I.
AU - Gershanovich, M. L.
AU - Karelin, M. I.
AU - Vorob'ev, A. V.
AU - Filov, V. A.
AU - Stukov, A. N.
N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 1998
Y1 - 1998
N2 - The results of an all-round examination and complex treatment of 323 patients with renal cell carcinoma were evaluated. Locally advanced tumors were diagnosed in 143 (44.3%) and extended ones--in 180 (66.7%). In patients with locally advanced tumor who had undergone nephrectomy after embolization or chemoembolization, 12-, 24- and 36-month survival rates showed no significant difference. In patients with extended renal carcinoma, 2- and 3-year survival was significantly higher after chemoembolization than after standard embolization of the renal artery.
AB - The results of an all-round examination and complex treatment of 323 patients with renal cell carcinoma were evaluated. Locally advanced tumors were diagnosed in 143 (44.3%) and extended ones--in 180 (66.7%). In patients with locally advanced tumor who had undergone nephrectomy after embolization or chemoembolization, 12-, 24- and 36-month survival rates showed no significant difference. In patients with extended renal carcinoma, 2- and 3-year survival was significantly higher after chemoembolization than after standard embolization of the renal artery.
UR - http://www.scopus.com/inward/record.url?scp=0032248591&partnerID=8YFLogxK
M3 - статья
C2 - 10087971
AN - SCOPUS:0032248591
VL - 44
SP - 711
EP - 714
JO - Вопросы онкологии
JF - Вопросы онкологии
SN - 0507-3758
IS - 6
ER -
ID: 74427691